Efficacy and Safety of Sofosbuvir/Velpatasvir in Patients With Chronic Hepatitis C Virus Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ASTRAL Trials

Jason Grebely, Gregory J. Dore, Stefan Zeuzem, Richard J Aspinall, Raymond Fox, Lingling Han, John McNally, Anu Osinusi, Diana M Brainard, G. Mani Subramanian, Macky Natha, Graham R Foster, Alessandra Mangia, Mark S. Sulkowski, Jordan J. Feld

Research output: Contribution to journalArticlepeer-review

Abstract

In this analysis of the ASTRAL trials (non-opioid substitution therapy [OST], n = 984; OST, n = 51) evaluating the once-daily, pan-genotypic regimen of sofosbuvir/velpatasvir for hepatitis C virus infection, OST did not impact completion, adherence, sustained virologic response (SVR12), or safety. SVR12 was 96% (95% confidence interval, 87%, >99%) in those receiving OST.

Original languageEnglish
Pages (from-to)1479-1481
Number of pages3
JournalClinical Infectious Diseases
Volume63
Issue number11
DOIs
Publication statusPublished - Dec 1 2016

Keywords

  • Journal Article

Fingerprint Dive into the research topics of 'Efficacy and Safety of Sofosbuvir/Velpatasvir in Patients With Chronic Hepatitis C Virus Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ASTRAL Trials'. Together they form a unique fingerprint.

Cite this